Isis Pharmaceuticals (NASDAQ: ISIS) has announced that it will be presenting an overview at the 2012 Credit Suisse Healthcare Conference on November 15. Isis, a prominent player in antisense therapeutics, saw its share prices increase by 14.6% to $8.79 after the announcement on Friday. In all, over 4 million shares changed hands during Friday’s trading session. Isis has been in the news recently as the FDA’s committee voted in favor of approving Isis’s Kynamro. Isis is expected to obtain approval from the EU by the year end for this product. Isis has already entered into a marketing pact with Genzyme (NASDAQ: GENZ) to promote Kynamro as soon as regulatory approvals are obtained.
Isis has also entered into partnerships with other drug manufacturers that provide for upfront and milestone-based payments. Isis is able to discover many drugs using its antisense platform and enters into partnerships to help develop and market specific drugs.
Antisense technology is used by pharmaceuticals to develop drugs that can help with a wide range of diseases such as cardiovascular, metabolic and rare diseases such as spinal muscular atrophy and TTR amyloidosis.
Antisense platforms help Isis build products that target a specific gene and bind to it, inhibiting the gene that causes a specific disease. Antisense drugs accumulate in the kidneys, liver and other organs helping to target diseases associated with them. Antisense drugs can be used to treat a broad range of diseases. The building blocks of antisense drugs across the spectrum are the same, making it easier to predict the safety profile, develop new drugs and manufacture them.
About Isis Pharmaceuticals
Isis is a leader in the antisense technology and has been using this to develop over 25 drugs to treat cardiovascular metabolic, and rare diseases. Isis partners with Genzyme and Biogen (NASDAQ: BIIB) to both develop and market its products in the U.S. and the EU. Isis discovers more drugs than it can develop using its antisense technology, and uses these partnerships to help develop and market various drugs. This strategy enables Isis to save on marketing and sales costs while benefitting from royalty payments.
Isis also uses RNA-based drug discovery, development and a patent strategy that ensures strong and extensive protection for drugs.
The news that Isis is set to make a presentation at the Credit Suisse Healthcare Conference has triggered investor interest. The share value increased by more than 14% on Friday as a substantial number of shares exchanged hands.
Other shares that saw a substantial increase in prices included Arena Pharmaceuticals (NASDAQ: ARNA) that saw a 10.4% increase to $8.36 with 14.6 million shares traded. Amarin (NASDAQ: AMRN) shares saw a 9.3% increase to $11.21 with 5.9 million shares traded. Another stock that saw a large volume of trade with a substantial increase in share price was Westport Innovations (NASDAQ: WPRT). Westport shares rose by 9.4% to $25.78 with 2.2 million shares traded.
For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com